Lou Pillai is the founder of Ulivmo and most recently, he was the Head of Data and Digital at Immunomedics (acquired by Gilead). Ehsan Ehsani is a director of consulting at CGI and leader of ...

George Korol graduated from the United States Naval Academy in May of 1993 and served as a 2nd lieutenant in the United States Marine Corps as an artillery officer for six years. He left the United ...

Arthur G. Cook is Principal, ZS Associates.

In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and ...

Taking the targeting of oncologists likely to start treatment with CAR-T as an example, validation studies show that targeting top-scored physicians from predictive models yields precision rates of 60 ...

Eli Lilly built up $1.5 billion in pre-launch inventory for its experimental oral weight-loss drug orforglipron, according to a regulatory filing.

The CEO of TransCelerate BioPharma Inc. She has been part of the organization since its inception in 2012 and has more than 20 years of experience leading initiatives in large pharma and biotech ...

PTC Therapeutics withdrew its New Drug Application (NDA) resubmission for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy (nmDMD) following feedback from FDA indicating that the ...

To be successful in the pharmaceutical industry, leaders must be willing to take risks. During his conversation with Pharmaceutical Executive, Leonard Mazur kept coming back to this point. According ...

Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, ...

In a conversation with Pharmaceutical Executive, Phesi founder and CEO Gen Li discusses his company’s recent global analysis of clinical trials. While the report once again showed that breast cancer ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.